Johnson & Johnson Aktie
WKN: 853260 / ISIN: US4781601046
21.05.2025 04:03:13
|
FDA Panel Votes In Favor Of J&J' DARZALEX FASPRO For High-Risk Smoldering Multiple Myeloma Treatment
(RTTNews) - Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) voted (6-2) in favor of the benefit-risk profile of single-agent DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM).
An application for the approval of DARZALEX FASPRO for adult patients with high-risk smoldering multiple myeloma was submitted to the FDA in November 2024.
The committee reviewed data from the AQUILA study, a Phase 3, randomized, open-label trial which evaluated the efficacy and safety of DARZALEX FASPRO versus SOC active monitoring in patients with HR-SMM.
The ODAC is convened upon request of the FDA to review and evaluate safety and efficacy data of human drug products for use in the treatment of oncologic diseases. The committee provides non-binding recommendations based on its evaluation; however, final decisions on approval of the drug are made by the FDA.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
14.10.25 |
Pluszeichen in New York: Dow Jones-Börsianer greifen zu (finanzen.at) | |
14.10.25 |
Ausblick: Johnson & Johnson gewährt Anlegern Blick in die Bücher (finanzen.net) | |
13.10.25 |
Börse New York in Grün: Dow Jones steigt (finanzen.at) | |
10.10.25 |
Minuszeichen in New York: Dow Jones präsentiert sich zum Handelsende schwächer (finanzen.at) | |
10.10.25 |
Verluste in New York: Dow Jones verbucht am Nachmittag Verluste (finanzen.at) | |
10.10.25 |
Börse New York: Dow Jones am Freitagmittag im Minus (finanzen.at) | |
09.10.25 |
Angespannte Stimmung in New York: Dow Jones fällt letztendlich zurück (finanzen.at) | |
09.10.25 |
Börse New York: Dow Jones sackt am Donnerstagnachmittag ab (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 163,64 | -0,41% |
|